Research Article
Metabolic Effects of Recombinant Human Growth Hormone Replacement Therapy on Juvenile Patients after Craniopharyngioma Resection
Table 1
Comparison of the GHRT and control group baseline characteristics.
| | Characteristic | GHRT group (n = 30) | Control group (n = 12) | |
| | Gender (male/female, n) | 25/5 | 10/2 | >0.999 | | Age (year) | 13.00 (8.00∼14.00) | 10.08 ± 3.42 | 0.241 | | Age at time of surgery (year) | 9.50 (5.38∼11.53) | 7.77 ± 3.46 | 0.477 | | Time sincere section (year) | 2.00 (1.62∼3.15) | 1.8(1.05∼2.65) | 0.354 | | LT4 dosage (µg/d/m2) | 45.84 ± 12.92 (n = 28) | 49.24 ± 22.45 (n = 10) | 0.660 | | Hydrocortisone dosage (mg/d/m2) | 10.10 ± 5.23 (n = 27) | 7.26 ± 6.05 (n = 11) | 0.156 | | Sex hormone supplement (n) | 11 | 1 | 0.128 | | rhGH dosage (µg/kg/d) | 19.98 ± 9.99 | 0 | 0.001 | | Desmopressin (n) | 28 | 12 | >0.999 | | Overweight or obese (n) (BMI-Z >1) | 20 (66.7%) | 11 (91.7%) | 0.133 | | IGF-1 <—2sd (n) | 25 | 8 | 0.406 |
|
|
